Anastrozole , ≥99% , 120511-73-1

Synonym(s):
Anastrozole;Arimidex;2;2"-[5-(1H-1;2;4-Triazol-1-ylmethyl)-1;3-Phenylene]bis(2-methyl-propiononitrile;a,a,a′,a′-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile

CAS NO.：120511-73-1

Empirical Formula: C17H19N5

Molecular Weight: 293.37

MDL number: MFCD00866298

EINECS: 601-715-6

PRODUCT Properties

• Melting point: 81-82°C
• Boiling point: 469.7±55.0 °C(Predicted)
• Density: 1.08±0.1 g/cm3(Predicted)
• storage temp.: room temp
• solubility: DMSO: soluble40mg/mL
• pka: 2.62±0.10(Predicted)
• form: solid
• color: White to off-white
• BCS Class: 1 (LogP), 3 (CLogP)
• InChI: InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3
• InChIKey: YBBLVLTVTVSKRW-UHFFFAOYSA-N
• SMILES: C(#N)C(C1=CC(CN2C=NC=N2)=CC(C(C#N)(C)C)=C1)(C)C

Description and Uses

Anastrozole(120511-73-1) was first approved for use in the United States in 1995 for the treatment of advanced breast cancer in post-menopausal women. Anastrozole is a highly potent and selective aromatase inhibitor. It is extremely potent in lowering circulating estradiol to undetectable levels in treated patients without altering other circulating hormones. The drug is reportedly well absorbed and tolerated following oral administration.

Anastrozole is a nonsteroidal inhibitor of aromatase which effectively blocks estrogen synthesis in postmenopausal women and is used as therapy of estrogen receptor positive breast cancer. Anastrozole has been associated with a low rate of serum enzyme elevations during therapy and rare instances of clinically apparent liver injury.

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Danger
• Hazard statements: H302-H360FD
• Precautionary statements: P202-P264-P270-P280-P301+P312-P308+P313
• Hazard Codes: Xi,Xn
• Risk Statements: 36/37/38-22-61-60
• Safety Statements: 26-37/39
• RIDADR: 3249
• WGK Germany: 3
• RTECS: CZ1465000
• HazardClass: 6.1(b)
• PackingGroup: III
• HS Code: 29339980